Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

1. TextEssence: A Tool for Interactive Analysis of Semantic Shifts Between Corpora.Proceedings of the conference. Association for Computational Linguistics. North American Chapter. Meeting · 2021
   Article
2. Reply.The Journal of allergy and clinical immunology · 2020
   Article
3. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.Frontiers in oncology · 2020
   Article

Corrections and comments

• Commented on by
  Reply.2020
• Comment on
  Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.2020

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as